130 related articles for article (PubMed ID: 14565477)
21. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
Roychowdhury D; Lahn M
Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
[TBL] [Abstract][Full Text] [Related]
22. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
[TBL] [Abstract][Full Text] [Related]
23. Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen.
Lahn M; Sundell K; Moore S
Ann N Y Acad Sci; 2003 Dec; 1002():263-70. PubMed ID: 14751841
[TBL] [Abstract][Full Text] [Related]
24. Specific inhibition of interleukin-10 production in murine macrophage-like cells by phosphorothioate antisense oligonucleotides.
Arima H; Takahashi M; Aramaki Y; Sakamoto T; Tsuchiya S
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):319-27. PubMed ID: 9743469
[TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Stein CA; Cheng YC
Science; 1993 Aug; 261(5124):1004-12. PubMed ID: 8351515
[TBL] [Abstract][Full Text] [Related]
26. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues.
Arzumanov A; Stetsenko DA; Malakhov AD; Reichelt S; Sørensen MD; Babu BR; Wengel J; Gait MJ
Oligonucleotides; 2003; 13(6):435-53. PubMed ID: 15025911
[TBL] [Abstract][Full Text] [Related]
27. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
28. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
[TBL] [Abstract][Full Text] [Related]
29. Antisense strategies targeting protein kinase C: preclinical and clinical development.
Tortora G; Ciardiello F
Semin Oncol; 2003 Aug; 30(4 Suppl 10):26-31. PubMed ID: 12917818
[TBL] [Abstract][Full Text] [Related]
30. Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells.
Wang XY; Repasky E; Liu HT
Exp Cell Res; 1999 Jul; 250(1):253-63. PubMed ID: 10388539
[TBL] [Abstract][Full Text] [Related]
31. Antisense suppresssion of protein kinase C-alpha and -delta in vascular smooth muscle.
Busuttil SJ; Morehouse DL; Youkey JR; Singer HA
J Surg Res; 1996 Jun; 63(1):137-42. PubMed ID: 8661186
[TBL] [Abstract][Full Text] [Related]
32. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.
Rubenstein M; Glick R; Lichtor T; Mirochnik Y; Chou P; Guinan P
Med Oncol; 2001; 18(2):121-30. PubMed ID: 11778757
[TBL] [Abstract][Full Text] [Related]
33. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
Gao WY; Han FS; Storm C; Egan W; Cheng YC
Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
[TBL] [Abstract][Full Text] [Related]
34. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.
Normanno N; Bianco C; Damiano V; de Angelis E; Selvam MP; Grassi M; Magliulo G; Tortora G; Bianco AR; Mendelsohn J; Salomon DS; Ciardiello F
Clin Cancer Res; 1996 Mar; 2(3):601-9. PubMed ID: 9816209
[TBL] [Abstract][Full Text] [Related]
35. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides.
Stewart AJ; Canitrot Y; Baracchini E; Dean NM; Deeley RG; Cole SP
Biochem Pharmacol; 1996 Feb; 51(4):461-9. PubMed ID: 8619891
[TBL] [Abstract][Full Text] [Related]
36. Identification of PKCalpha isoform-specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides.
Kerkelä R; Ilves M; Pikkarainen S; Tokola H; Ronkainen J; Vuolteenaho O; Leppäluoto J; Ruskoaho H
Mol Pharmacol; 2002 Dec; 62(6):1482-91. PubMed ID: 12435817
[TBL] [Abstract][Full Text] [Related]
37. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo.
Monia BP; Sasmor H; Johnston JF; Freier SM; Lesnik EA; Muller M; Geiger T; Altmann KH; Moser H; Fabbro D
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15481-4. PubMed ID: 8986837
[TBL] [Abstract][Full Text] [Related]
38. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
40. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development.
Holmlund JT
Ann N Y Acad Sci; 2003 Dec; 1002():244-51. PubMed ID: 14751839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
